Antibody-based medicine including monoclonal antibodies, Fcfusion and scFv development, characterisation and formulation.
- Biotherapeutics formulation and stability determination
- Bispecific antibody mimetic for ocular disease
Subcutaneous formulation of antibody-based medicine; stability determination
There is an unmet clinical need to develop the stable antibodybased drug for patient self-administration (subcutaneous) for chronic diseases. The opportunity to make such a stable drug to also have a sustainable drug release profile, could potentially revolutionise healthcare by delivering new medicine with effective treatment of diseases. There are challenges to formulate protein-based drug for subcutaneous administration such as stability and viscosity since high protein concentration required to achieve the subcutaneous dose.
The main aim of this project is, therefore, to address the instability of protein of interest (such as aflibercept) at high concentrations. Different approaches are taken to address our aims such as lyophilisation method to stabilise proteins, hydrogel-based system for releasing of bioactive drug in a controlled and sustained manner.
Bispecific antibodies for ocular indication
Ocular drug delivery of biologics to the back of the eye is an important and rapidly developing field of research because of their applications in treatment of ocular neovascularisation disease such as age-macular degeneration (AMD) and inflammation (uveitis).
Most approved antibody therapies are monospecific and are only able to bind to one target epitope. Bispecific therapies can potentially interact with two different targets to provide synergistic effects for greater clinical benefit than monospecific therapies. While there are 3 approved bispecific antibodies for oncology, none has been approved for ocular indication.
My research group has been working on development of novel bispecific antibody mimetic to treat ocular indications. This is a collaborative research with UCL School of Pharmacy.